Evaluation of plasma EGFR mutation as an early predictor of response of erlotinib plus bevacizumab treatment in the NEJ026 studyTatsuro Fukuhara, Makoto Maemondo, Naoki Furuya et al.|EBioMedicine|2020Cited by 30